BioAtla faces an existential liquidity crisis as its clinical-stage business model fails to generate sustainable revenue, evidenced by a TTM revenue of only $2.0 million.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest Mar 31, 2026 | -$8.00+33.3% vs -$12.00 | $2M+185.7% vs $700,000 |
Q4 2025 Nov 13, 2025 | -$0.27+12.9% vs -$0.31 | — vs — |
Q3 2025 Aug 7, 2025 | -$0.31-6.9% vs -$0.29 | — vs — |
Q2 2025 May 6, 2025 | -$0.29-3.6% vs -$0.28 | — vs — |
Benchmark BCAB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BioAtla, Inc. (BCAB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.52 | $2.52M | -0.03 | -81.82% | -2980.35% | — | — | |
| $30.53 | $6.3B | -11.02 | — | -7585.86% | -69.59% | — | |
| $18.28 | $2.3B | -5.56 | -4.26% | -386.32% | -87.98% | — | |
| $7.15 | $297.74M | -2102.94 | 10.37% | 69.76% | — | — | |
| $2.33 | $148.1M | -1.97 | 0.78% | -8.7% | -31.27% | — | |
| $1.84 | $213.89M | -1.60 | -51.24% | -1941.09% | -65.08% | — |
BioAtla, Inc. (BCAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
BioAtla, Inc. (BCAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 16, 2026·SEC
Apr 2, 2026·SEC
Mar 31, 2026·SEC
Get notified when BCAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioAtla, Inc. (BCAB) stock FAQ — growth, dividends, profitability & financials explained
BioAtla, Inc. (BCAB) reported $8.5M in revenue over the trailing twelve months. Revenue was $2.0M in fiscal year 2025. That is 81% less than the $10.6M of fiscal year 2018.
BioAtla, Inc. (BCAB) revenue fell by 81.8% in fiscal year 2025, compared with the prior fiscal year.
No. BioAtla, Inc. (BCAB) reported a net loss of $31.5M over the trailing twelve months.
BioAtla, Inc. (BCAB) had negative free cash flow of $23.5M over the trailing twelve months.
